L-165,041 Property

Melting point:

127-128 °C(lit.)

Boiling point:

600.8±55.0 °C(Predicted)

Density 

1.222±0.06 g/cm3(Predicted)

storage temp. 

2-8°C

solubility 

DMSO: >10 mg/mL

form 

solid

pka

3.23±0.10(Predicted)

color 

off-white

Stability:

Light Sensitive

Safety

WGK Germany 

3

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

L-165,041 Chemical Properties,Usage,Production

Uses

L-165,041 has been used as a peroxisome proliferator-activated receptor β/δ (PPARβ/δ) ligand to study its influence on PPARβ/δ mediated postnatal myogenesis in C2C12 myoblasts.

Definition

ChEBI: 2-[4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy]acetic acid is an aromatic ketone.

General Description

A cell-permeable phenoxyacetic acid derivative that acts as a potent and selective peroxisome proliferator activator receptor δ (PPARδ) agonist (K_i = 6 nM for hPPARδ and 730 nM for hPPARγ). Potently induces adipocyte differentiation in NIH-PPARδ cells at 500 nM and raises total cholesterol in insulin resistant db/db mice without altering glucose or triglycerides levels. Increases UCP3 (uncoupling protein 3) gene expression in L6 myotubes. Inhibits cytokine-induced expression of VCAM-1 (vascular cell adhesion molecule-1) and the secretion of MCP-1 (monocyte chemotactic protein-1) in EAhy926 cells.

Biological Activity

Potent PPAR δ agonist (K i = 6 nM); displays > 100-fold selectivity for both mouse and human PPAR δ ? receptors over other subtypes. In vivo, raises plasma cholesterol levels in insulin-resistant db/db mice and is neuroprotective in models of cerebral infarction and Parkinson's disease.

Biochem/physiol Actions

Cell permeable: yes

in vitro

l-165041, which is a selective and potent pparδligand, displayed in this specified transactivation system, apart from its highly efficacious pparδ agonist activity, partial and full agonism at, respectively, pparγ2 and pparαsubtypes [1].

in vivo

l-165041 could drastically reduce lipid accumulation in the mouse liver, decreasing total hepatic triglyceride and cholesterol content compared to the vehicle group. gene analysis demonstrated that l-165041 lowered hepatic expression of pparγ, apolipoprotein b, il-1β, and interleukin-6. in contrast, l-165041 increased hepatic expressions of pparδ, lipoprotein lipase, and atp-binding cassette transporter g1 (abcg1) [2].

target

PPARδ

storage

Desiccate at RT

References

[1] wurch t, junquero d, delhon a, pauwels j. pharmacological analysis of wild-type alpha, gamma and delta subtypes of the human peroxisome proliferator-activated receptor. naunyn schmiedebergs arch pharmacol. 2002 feb;365(2):133-40.
[2] lim hj, park jh, lee s, choi he, lee ks, park hy. ppardelta ligand l-165041 ameliorates western diet-induced hepatic lipid accumulation and inflammation in ldlr-/- mice. eur j pharmacol. 2009 nov 10;622(1-3):45-51.